Fluoroglutamate-containing analogs of folates and
methotrexate (MTX) with altered capacities for
poly (gamma-glutamate) metabolism were synthesized to probe the
biological roles of polyglutamates. Compared to
folic acid, DL-e,t-
gamma-fluorofolic acid, a compound that is a poor substrate for polyglutamylation, was approximately 25-fold less potent in promoting growth of
folate-depleted H35 rat
hepatoma cells. DL-
beta,beta-Difluorofolic acid, a compound that forms diglutamates more readily than does
folic acid, was at least equivalent to
folic acid in potency.
Leucovorin (LV), a reduced
folate, was 30-fold more potent than
folic acid in promoting growth, whereas the analogous form of DL-e,t-gamma-fluorofolate, DL-e,t-gamma-fluoroleucovorin (DL-e,t-gamma-FLV) was only 4-fold more potent than
folic acid. Both LV and DL-e,t-gamma-FLV protected or "rescued" cells from the growth inhibitory effects of MTX; however a 37- to 46-fold higher concentration of the fluoro analog was required.
Folic acid, DL-e,t-
gamma-fluorofolic acid, LV, and DL-e,t-gamma-FLV each potentiated the growth inhibitory effect of
5-fluoro-2'-deoxyuridine on CCRF-CEM human
leukemia cells; higher concentrations of fluorinated analogs again were required. Stereochemically pure L-t-
gamma-fluoromethotrexate (L-t-gamma-
FMTX), a poor substrate for polyglutamylation, was evaluated as a
cell growth inhibitor. In continuous exposure, L-t-gamma-
FMTX), was 7-fold less potent than MTX as an inhibitor of CCRF-CEM growth. Results with these fluorinated
folate and MTX analogs offer insight into the importance of
polyglutamate metabolism to these
biological and pharmacological effects.